Proliferation and migration of vascular smooth muscle cells (VSMCs) can cause atherosclerosis and neointimal formation. MicroRNAs have been shown to regulate cell proliferation and phenotype transformation. We discovered abundant expression of microRNA-195 in VSMCs and conducted a series of studies to identify its function in the cardiovascular system.
Introduction
Cardiovascular disease is one of the leading causes of death in developed countries. Oxidized low-density lipoprotein (oxLDL) has been shown to play a critical role in the development of atherosclerosis by stimulating the proliferation of vascular smooth muscle cells (VSMCs) within the vessel walls and by other mechanisms. 1 Loss of vascular endothelial cells due to mechanical removal (such as hemodynamic forces and stenting) or cell apoptosis can induce VSMC migration from the media into the intima. Subsequently, VSMC can proliferate in the intima, resulting in neointimal hyperplasia and plaque formation. Therefore, VSMC proliferation is a common feature in the development of atherosclerosis and arterial stenosis after endothelial injury. MicroRNAs (miRNAs) are noncoding, single-stranded RNA molecules of 21-23 nucleotides. 2 Within the cell nucleus, miRNA is first transcribed as pri-miRNA with a cap and poly-A tail, and then processed to a short, 70-nucleotide stem-loop structure known as pre-miRNA. 3 The pre-miRNA is further processed to mature miRNA in the cytoplasm. A mature miRNA is complementary to a part of one or more mRNAs. Animal miRNAs are usually complementary to a site in the 3 ′ untranslated region (UTR) of mRNA.
Annealing of miRNA to the mRNA causes inhibition of protein translation and/or cleavage of the mRNA. Thus, miRNAs regulate cell growth, differentiation, and apoptosis, 4 -6 and deregulation of miRNA expression may lead to human diseases. Consequently, much research has focused on the role of miRNAs in cancers, as cell dedifferentiation, growth, and apoptosis are important cellular events in tumorigenesis. 7, 8 However, recent studies have shown that miRNA also plays a key role in the cardiovascular system. 9 -14 For example, it was found that miR-145 is a marker for VSMC and regulates vascular neointimal lesion formation, 13 and that miR-29b can influence DNA methylation of MMP-2/MMP-9 genes, which leads to an increased risk of cardiovascular disease. 14 More information can be found in recent review articles. 15, 16 In the present study, we identified abundant expression of miR-195 in VSMCs. Previous studies have demonstrated that miR-195 can inhibit cell cycle progression and proliferation of different cancer cell types. 17 -19 However, whether miR-195 is involved in cardiovascular disease remains to be determined. Consequently, we tested its role in the cardiovascular system using both cellular and animal studies. Mechanisms to explain the effects of miR-195 are also discussed. per well on collagen coated 12-well plates and maintained at 378C in a 5% CO 2 atmosphere. Cells were subcultured when they reached 70 -80% confluence. OxLDL (Biomedical Technologies, Inc., Stoughton, MA, USA) was used to induce atherosclerotic changes in HASMCs, including increased cell proliferation, cell migration, and production of inflammatory markers. Total RNA was extracted with Trizol reagent (Invitrogen, Carlsbad, CA, USA). The ABI Taqmanw microRNA low density array (TLDA; Applied Biosystems, Foster City, CA, USA), which includes 667 human microRNAs, was used to generate the miRNA expression profile. Due to budgetary restrictions, the array experiment was performed only once. Data were normalized to the internal control (small RNA RU6B). Real-time PCR was performed for Hsa-miR-195 (UAGCAGCACAGAAAUAUUGGC; Assay ID: 000494) using a TaqMan miRNA Reverse Transcription kit (Applied Biosystems).
Methods
For PCR experiments, water without cDNA template was used as a negative control. All the reactions were amplified in a 7900HT Fast Real Time PCR system (Applied Biosystems). Expression levels of miRNA were quantified by employing the 2 -DDCt relative quantification method.
Cell proliferation and migration assay
To examine the effect of miR-195 on cell proliferation, HASMCs were transfected with different doses of miR-195 precursor and incubated in microplates at 378C with 5% CO 2 for 24 h. Dimethyl-thiazoldiphenyltetrazoliumbromide (MTT; Sigma -Aldrich, St Louis, MO, USA) was then added (0.5 mg/mL in each well). Cell proliferation was evaluated by using an X340 spectrophotometer at 595 nm (BioTek, Winooski, VT, USA). To assess cell migration in vitro, 5 × 10 4 cells were placed in the 24-well Millicell Hanging Cell Culture Insert (Millipore, Billerica, MA, USA) chamber that has 8 mm pore polyethylene terephthalate (PET) membranes. Then, oxLDL (20 mL, 40 mg/mL) was added to the lower chamber to induce cell migration. After 6 h, non-migrating cells were removed from the upper surface of the transwell membrane with a cotton swab, and migrating cells on the lower surface of the membrane were fixed, stained, photographed in a microscope at ×100 magnification, and counted. 
Preparation of stable cells

Transcriptome
Total RNA was obtained from clone over-expressing miR-195 and from the control clone, and cDNA microarray analyses were performed using the Human Whole Genome OneArray (Phalanx Biotech Group, Hsinchu, Taiwan; see Supplementary Methods). Functional annotation of genes was performed by using Ingenuity Pathways Analysis (IPA; Ingenuity Systems, Redwood City, CA, USA).
Construction of adenovirus expressing miR-195 and control adenovirus expressing GFP
Adenovirus expressing miR-195 (Ad-miR-195) and control adenovirus expressing GFP (Ad-GFP) were generated using the RAPAd miRNA Adenoviral Expression System kit (Cell Biolabs) according to the manufacturer's protocol. Adenoviruses was amplified by infecting HEK293AD cells, and then purified by using a ViraBind Adenovirus Miniprep kit (Cell Biolabs) followed by titration with a QuickTiter Adenovirus Titer Immunoassay kit (Cell Biolabs).
Rat model for balloon-injured carotid artery and miRNA transfection
The Animal Care and Use Committee of the Kaohsiung Medical University approved the animal experimental protocols, which strictly conformed to the Guide for the Care and Use of Laboratory Animals, 8th Edition (2011). The balloon-injured carotid arteries were produced in male Sprague -Dawley (SD) rats (300 -350 g). Rats were sedated with isoflurane ('Forane'; Abbott Laboratories Ltd., Queenborough, Kent, UK), anaesthetized by intraperitoneal administration of ketamine hydrochloride (72 mg/kg; Sigma -Aldrich) and xylazine hydrochloride (5 mg/kg; SigmaAldrich). The depth of anesthesia was confirmed by the lack of tail-pinch-induced pain reflex, a commonly used method in monitoring the depth of anesthesia in rats receiving survival surgery. The external carotid artery and the right internal carotid artery were exposed by a neck incision under a microscope (Carl Zeiss OPMI pico, Oberkochen, Germany). A 2F Fogarty catheter (Baxter-Edwards, CA, USA) was advanced to the proximal edge of the omohyoid muscle. The balloon on the catheter was inflated with saline and then withdrawn; this was repeated three times. After the injury, a suspension of Ad-miR-195 or Ad-GFP at 6.25×10 7 plaque-forming units (pfu)/mL was infused into the ligated segment of the common carotid artery for 30 min (n ¼ 6 for each group). After four weeks, rats were sacrificed by overdose isoflurane exposure. Each rat was placed in a small desiccator chamber with a 2 ′′ × 2 ′′ piece gauze soaked with isoflurane. The transparent lid of the desiccator was quickly closed. Surgery to collect the carotid artery was performed after the rat in the desiccator stopped breathing. The entire
length of the right carotid artery 10 was balloon injured. The left carotid artery served as an uninjured intra-animal control. Histological examination was performed with hematoxylin and eosin stain using 8 mm sections of carotid rings.
Statistical analysis
All values in the text and figures are expressed as mean + SD. Statistical differences were evaluated by Student's t-test or ANOVA. P-values ,0.05 were considered statistically significant in all experiments. Analysis of the data and plotting of the figures were performed by using SigmaPlot version 10 (Systat Software Inc., San Jose, CA, USA). Online supplementary files are available as Supplementary material at Cardiovascular Research online.
Results
MicroRNA array analysis of HASMCs
To identify miRNAs that may modulate VSMC phenotype, we first used the miRNA arrays to survey miRNA expression levels in HASMCs with and without treatment of oxLDL (40 mg/mL). Of the 667 surveyed miRNAs, 103 had decreased expression (by at least two-fold) in the cells treated with oxLDL; miR-195 was decreased 13-fold (Supplementary material online, Table S1 ). The fold change in miR-195 was comparable to those of other miRNAs that had previously been reported to be associated with cardiovascular phenotypes, such as miR-145 and miR-221. 11 -13 Since miR-195 had not been reported in the cardiovascular system at the time we conducted this study, we decided to further analyse its role in the cardiovascular system.
Effects of miR-195 on VSMC
We compared the miR-195 levels in HASMCs, human umbilical vein endothelial cells, and macrophages, and found that miR-195 was more abundant in HASMCs than in the other two cell types ( Figure 1A ). To investigate a potential role of miR-195 in the HASMC phenotype change, we first evaluated the viability of HASMCs following transfection of miR-195 precursor, inhibitor, or negative control miRNA into HASMCs. The transfection efficiency of miR-195 precursor/inhibitor and the negative control in HASMCs was assessed by a miR-195-specific RT -PCR assay. miR-195 precursor (25, 50, 75 , and 100 nM) caused a dose-dependent increase in intracellular miR-195 levels, whereas miR-195 inhibitor reduced intracellular miR-195 levels in a dose-dependent fashion (Supplementary material online, Figure S1 ).
To test the effect of miR-195 on HASMC proliferation, we determined mitochondrial activity by the MTT assay; we also quantified DNA synthesis by measuring incorporation of bromodeoxyuridine (BrdU). The MTT assay demonstrated that oxLDL (40 mg/mL) increased HASMC proliferation 1.4-fold (P , 0.001) at 24 h ( Figure 1B) . Compared with HASMCs treated with only oxLDL, HASMCs transfected with the miR-195 precursor (25, 50, 75 , and 100 nM) showed a concentration-dependent reduction of proliferation at 24 h after oxLDL treatment (P , 0.001). Consistent with the result from the MTT assay, miR-195 precursor (100 nM) substantially attenuated DNA replication ( Figure 1C ) as indicated by reduced BrdU incorporation (from 89 to 10%) in oxLDL-treated HASMCs.
For cell migration, oxLDL strongly promoted HASMC migration (212% relative to basal level) after 6 h incubation. The migration was suppressed (by 41%) when oxLDL-treated HASMCs were transfected with 50 nM miR-195 precursor ( Figure 2) . In contrast, HASMC migration increased by 12% when oxLDL-treated HASMCs were transfected with 50 nM miR-195 inhibitor. In addition, transfection of miR-195 precursor (50 nM) reduced the levels of IL-1b, IL-6, and IL-8 (IL-1b, P , 0.05; IL-6, P , 0.01; Table 1 ) in the culture medium of oxLDL-treated HASMCs. In the absence of oxLDL, miR-195 precursor did not change the levels of these interleukins ( Table 1) . Our data show that miR-195 can protect against the oxLDL-induced deleterious effects on VSMCs, as determined by cell proliferation, migration, and secretion of inflammatory cytokines.
miR-195 down-regulates CCND1 and Cdc42
To identify the miR-195 target genes, we first constructed a clone stably over-expressing miR-195. This clone showed a three-fold increase in miR-195 level at the third and sixth passages (Supplementary material online, Figure S2 ). Subsequently, we used cDNA arrays to compare gene expression between the stable clone over-expressing miR-195 precursor (50 nM) was transfected to HASMCs with or without oxLDL treatment (40 mg/mL). After 24 h, culture medium was collected and protein levels of IL-1b, IL-6, and IL-8 were determined using ELISA. Data are presented as mean + SD from three independent experiments performed in triplicate. *P , 0.05 and **P , 0.01 were from the comparison between NC-miR and miR-195 in the oxLDL group. NC-miR: negative control miR.
miR-195 and a control clone. From the transcriptome data, 136 genes were found to be significantly down-regulated (fold change ,0.5, P , 0.05) in the stable clone. We tested these differentially expressed genes for enrichment in functional annotation groups as determined by IPA. The IPA analysis showed that these genes are mainly involved in cell cycle control, proliferation, development, morphology, signalling, and interaction. The 10 most prominent biological functions are listed in Figure 3A .
To confirm the effects of miR-195 on these genes, we measured their protein levels in the presence of different concentrations of miR-195 precursor. Western blotting showed that the expression of both genes was reduced by miR-195 precursor in a dosedependent manner (25 -100 nM; Figure 3B ). We then knocked down each target gene separately with specific short hairpin RNA (shRNA). Interestingly, we noticed that when Cdc42 was knocked down, the expression of CCND1 was simultaneously reduced (by 30%, P , 0.001; Figure 4A ). However, when CCND1 was knocked down, the expression of Cdc42 was increased. Transfection of either CCND1 or Cdc42 shRNA into oxLDL-treated HASMCs inhibited cell proliferation at 24 h ( Figure 4B ; P , 0.001). Based on the above findings and previous studies, 23 -25 we speculated that (i) the effect of miR-195 on the cardiovascular system is primarily through interaction with Cdc42, and (ii) CCND1 down-regulation may be not only a consequence of miR-195 targetting but also of downstream effects of Cdc42 inhibition. In addition to Cdc42 and CCND1, FGF1 was observed to be down-regulated in our cDNA array experiment (data not shown OxLDL-treated HASMCs were transfected with miR-195 precursor or a negative control miR (NC-miR). CCND1 and Cdc42 protein expression in HASMCs was measured by western blot at 24 h post-transfection. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a control. Data are presented as mean + SD from three independent experiments, and each experiment was performed in triplicate. *P , 0.05, **P , 0.01, and ***P , 0.001 were from the comparisons between oxLDL plus NC-miR treatment and other treatments. growth factor in angiogenesis. The array finding was supported by the discovery that oxLDL-induced FGF1 expression was reduced by miR-195 precursor, and that HASMC proliferation could be repressed by FGF1 shRNA (Supplementary material online, Figure S3 ).
Cdc42 is a direct target of miR-195
We then used a luciferase reporter assay with wild-type or mutant miR-195 binding sequences of the Cdc42 3 ′ -UTR, to confirm direct binding of miR-195 to the Cdc42 gene ( Figure 5A, upper panel) . Transfection of the miR-195 precursor led to a significant decrease in luciferase activity for the plasmid bearing the wild type sequence of Cdc42 3 ′ -UTR ( Figure 5A lower panel) . In contrast, the miR-195 precursor had no effect on luciferase activity for the plasmid bearing the mutant sequence of Cdc42 3 ′ -UTR. To further prove that miR-195
regulates Cdc42 and CCND1 gene expression, we transfected miR-195 precursor or inhibitor into the oxLDL-treated HASMCs.
The results showed that both Cdc42 and CCND1 protein levels were reduced by 50 nM miR-195 precursor at 24 h ( Figure 5B ), whereas they were increased by miR-195 inhibitor at 24 h. These findings indicated that miR-195 down-regulated Cdc42 and CCND1 expression, and our study confirmed that Cdc42 is a direct target of miR-195 in human cells.
MiR-195 reduces neointimal formation in the balloon-injured rat carotid artery
Given that the miR-195 sequence is conserved among different species (Supplementary material online, Figure S4 ), it is likely that its function is similarly comparable. Since miR-195 can reduce inflammation and cell proliferation, we speculated that miR-195 may inhibit neointimal formation after injury to the vascular intima. To test this hypothesis, we applied miR-195 gene therapy in a balloon-injury rat model. We first measured the expression of endogenous miR-195 in the rat carotid artery after balloon injury. The expression level of endogenous miR-195 was significantly (80%) lower in the injured arteries, compared to that in uninjured arteries ( Figure 6A ; P ¼ 0.007). Next, we assessed the efficacy of Ad-miR-195 and Ad-GFP delivery into HASMCs. Cells infected with Ad-miR-195 (250 MOI) showed a 15-fold increase in miR-195 expression compared with The mRNA levels of CCND1 and Cdc42 were measured with real-time PCR. Knockdown of Cdc42 also caused down-regulation of CCND1 (upper panel), but there was an increase of Cdc42 when CCND1 was knocked down (lower panel). (B) CCND1-and Cdc42-specific shRNAs inhibited proliferation of oxLDL-treated HASMCs. Two negative controls were used: no transfection, and an unrelated shRNA (NC-shRNA). Data are presented as mean + SD from three independent experiments, and each experiment was performed in triplicate.
cells infected with Ad-GFP (Supplementary material online, Figure  S5 ), thus indicating that Ad-miR-195 can successfully synthesize miR-195 after infecting the cells. Then, 24 h after successful adenoviral infection, oxLDL (40 mg/mL) was used to induce HASMC proliferation. As expected, miR-195 overexpressed by Ad-miR-195 significantly decreased HASMC proliferation ( Figure 6B ). When Ad-miR-195 was administered to the balloon-injured carotid artery in vivo, neointimal formation was substantially reduced ( Figure 6C , upper panel and Figure 6D ). To confirm that inhibition of neointimal formation was mediated by Ad-miR-195 restoring the down-regulated miR-195, we performed in situ hybridization (ISH) on carotid artery sections. The ISH experiment showed that miR-195 was present in both the VSMCs at the vessel intimal layer and fibroblasts at the medial layer of the Ad-miR-195-treated arteries ( Figure 6C, middle panel) . In contrast, miR-195 was not detected in Ad-GFP-treated arteries. IHC showed Cdc42 to be more abundant in the neointima of the Ad-GFP-treated arteries than in Ad-miR-195-treated arteries ( Figure 7 ). Cdc42 protein was found primarily in both the endothelial cells and VSMCs of neointima. These results suggest that increased Cdc42 protein in the balloon-injured artery led to neointimal growth, and that miR-195 suppressed expression of Cdc42 thereby resulting in the inhibition of neointimal formation.
Discussion
We found that HASMC miR-195 levels were different when cells were treated with oxLDL. MiR-195 levels were much higher in HASMCs than in vascular endothelial cells or macrophages, which suggests that its expression is tissue specific. Based on our cellular studies, miR-195 modulated VSMC proliferation, migration, and the production of proinflammatory biomarkers. MiR-195 down-regulated Cdc42, CCND1, and FGF1, all of which are involved in cell cycle control, migration, and proliferation. Using an animal model, miR-195 was demonstrated to prevent neointimal growth in balloon-injured carotid artery. The therapeutic effect may be primarily mediated by inhibition of Cdc42, which in turn prevents activation of its downstream signalling pathway. The proliferation and migration of VSMCs along with the production of pro-inflammatory biomarkers are deleterious factors in proliferative vascular diseases. 26, 27 IL-6 and IL-8 can promote DNA synthesis in VSMCs and cause cell proliferation. 28 -30 In this study, these cytokines were significantly reduced when HASMCs were transfected with miR-195. We also observed a significant decrease in IL-1b mRNA expression in the stable clone over-expressing miR-195. In addition, our cDNA array studies showed that expression of NFkB and p38 MAPK were reduced in the stable clone over-expressing miR-195 (Data not shown). Indeed, previous studies have demonstrated that IL-6 and IL-8 can be activated by NFkB 31 and p38 MAPK, 32 -34 both of which can be induced by IL-1b. Accordingly, over-expression of miR-195 can reduce the expression of IL-6, IL-8, IL-1b, NKkB, and p38 MAPK concomitantly. Taken together, our results suggested that miR-195 can suppress the proliferative vascular disease by a variety of intracellular signalling cascades, including the p38 and NFkB pathways. 35 -37 Accumulating evidence indicates that miR-195 could play an inhibitory role in several diseases and tumorigenesis by regulating cellular pathways, such as cell proliferation, cell cycle control, and apoptosis. 17, 18, 38, 39 Furthermore, miR-195 may be a potential therapeutic and diagnostic target. 40 Cdc42 and CCND1 were initially predicted to be miR-195 target genes, and several previous studies have confirmed the effect of miR-195 on CCND1. 17, 19, 41 In this study, we demonstrated that when miR-195 was over-expressed, the mRNA and protein levels of both target genes were down-regulated. The reporter assay further confirmed direct binding of miR-195 to the Cdc42 3 ′ -UTR. Our experiments also demonstrated the involvement of Cdc42 and CCND1 in VSMC proliferation. Cdc42 is a Rho-GTPase that transduces extracellular signals to potentiate VSMC proliferation and migration. 42 -44 Our studies also found that the CCND1 gene is not only a direct target of miR-195 but also a sequential downstream effector of Cdc42. CCND1 plays an important role in regulating cell cycle transition from the G1 to S phase, 45, 46 and is primarily involved in DNA synthesis. A recent study also reported that CCND1 participated in neointimal formation of balloon-injured vascular walls. 47 Knockdown of CCND1 has also been shown to inhibit the proliferation of homocysteine-treated VSMCs. From our cDNA array data, we found that FGF1 expression was significantly suppressed in VSMCs with over-expressed miR-195 (data not shown). FGF1 is an important angiogenic growth factor that can induce VSMC proliferation and migration. 49, 50 FGF1 has been reported to enhance neointimal formation in aortic explants. 51 More interestingly, Cdc42, CCND1, and FGF1 are functionally related, and are in the same signalling pathway. Cdc42 is a downstream effector of phosphoinositide 3-kinase (PI3K) and it can stimulate both CCND1 24, 25 and FGF1 23 expression. Using RNA interference, we also obtained evidence that implies that Cdc42 serves as an upstream signal to activate the downstream CCND1 and FGF1 (Supplementary material online, Figure S6 ). Arterial neointimal formation is a major unwanted reaction following arterial stenting, which often requires patients to undergo a repeat of the angioplasty procedure. VSMC proliferation and migration with subsequent synthesis of extracellular matrix are central cellular events during neointimal formation. Recent studies have demonstrated that miRNAs may play an important role in the neointimal growth. 11 -13 In the present study, we found that expression of endogenous miR-195 was substantially decreased in the balloon-injured arteries. Following use of the adenovirus-mediated method to deliver miR-195 to the balloon-injured arteries, the neointimal formation was significantly suppressed in the region where miR-195 was detected. Therefore, an increase of endogenous miR-195 or exogenously administered miR-195 may reduce the necessity for re-stenosis in patients receiving arterial stenting.
Conclusions
We identified that miR-195 is involved in the modulation of VSMC and can suppress pro-inflammatory interleukins synthesized in VSMCs. Administering miR-195 substantially reduces neointimal formation, and thus they possesses therapeutic potential. The therapeutic effect of miR-195 is likely to be mediated by Cdc42, CCND1, and FGF1, as well as the anti-inflammatory effect.
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